AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
10 Feb 2021 07:00 AM
RNS
Divestment of Crestor in Europe completed
05 Feb 2021 07:00 AM
RNS
Update on KESTREL Phase III trial for Imfinzi
04 Feb 2021 07:00 AM
RNS
Forxiga approved in China for heart failure
01 Feb 2021 03:00 PM
RNS
Total Voting Rights
01 Feb 2021 12:15 PM
RNS
AstraZeneca agrees to divest Viela shareholding
01 Feb 2021 07:00 AM
RNS
COVID-19 vaccine authorised for use by the EU
29 Jan 2021 03:16 PM
RNS
COVID-19 vaccine receives positive opinion in EU
26 Jan 2021 03:00 PM
RNS
Block listing application
26 Jan 2021 07:00 AM
RNS
Symbicort approved in China for mild asthma
25 Jan 2021 07:05 AM
RNS
Calquence approved in Japan for CLL
25 Jan 2021 07:00 AM
RNS
Calquence met primary endpoint against ibrutinib
20 Jan 2021 07:00 AM
RNS
Enhertu approved in the EU for breast cancer
18 Jan 2021 07:00 AM
RNS
Enhertu approved in the US for gastric cancer
15 Jan 2021 07:00 AM
RNS
Imfinzi new dosing approved in EU
06 Jan 2021 07:00 AM
RNS
Farxiga granted US Priority Review for CKD
04 Jan 2021 03:00 PM
RNS
Total Voting Rights
04 Jan 2021 07:00 AM
RNS
Atacand divestment in over 70 countries completed
30 Dec 2020 07:00 AM
RNS
AstraZeneca's COVID-19 vaccine authorised in UK
29 Dec 2020 07:00 AM
RNS
Lynparza approved in Japan for three cancers
21 Dec 2020 07:05 AM
RNS
Tagrisso approved in the US for early lung cancer
21 Dec 2020 07:00 AM
RNS
Update on US regulatory review of roxadustat
17 Dec 2020 04:00 PM
RNS
Director/PDMR Shareholding
16 Dec 2020 06:15 PM
RNS
Director/PDMR Shareholding
15 Dec 2020 07:00 AM
RNS
Imfinzi new dose receives positive EU CHMP opinion
14 Dec 2020 07:05 AM
RNS
Trastuzumab deruxtecan positive CHMP
14 Dec 2020 07:00 AM
RNS
Trixeo Aerosphere approved in the EU for COPD
14 Dec 2020 07:00 AM
RNS
AstraZeneca to acquire Alexion Pharmaceuticals Inc
01 Dec 2020 03:00 PM
RNS
Block listing Interim Review
01 Dec 2020 03:00 PM
RNS
Total Voting Rights
01 Dec 2020 07:00 AM
RNS
Crestor to be divested to Grünenthal in Europe
30 Nov 2020 07:00 AM
RNS
Forxiga approved in Japan for heart failure
23 Nov 2020 07:00 AM
RNS
AZD1222 vaccine effective against COVID-19
20 Nov 2020 07:00 AM
RNS
Imfinzi new dosing approved in the US
10 Nov 2020 07:00 AM
RNS
Tezepelumab Phase III trial met primary endpoint
09 Nov 2020 07:00 AM
RNS
Calquence approved in the EU for CLL
06 Nov 2020 07:00 AM
RNS
Brilinta approved in the US in stroke
05 Nov 2020 07:15 AM
RNS
Lynparza approved in the EU for wider ovarian use
05 Nov 2020 07:10 AM
RNS
Lynparza approved in the EU for prostate cancer
05 Nov 2020 07:05 AM
RNS
Forxiga approved in the EU for heart failure
05 Nov 2020 07:00 AM
RNS
AZN: Year-to-date and Q3 2020 results
02 Nov 2020 03:00 PM
RNS
Total Voting Rights
30 Oct 2020 07:00 AM
RNS
Atacand to be divested in more than 70 countries
29 Oct 2020 07:00 AM
RNS
Directorate Change
28 Oct 2020 07:03 AM
RNS
Enhertu US Priority Review in gastric cancer
28 Oct 2020 07:00 AM
RNS
Forxiga CV outcomes benefit approved in China
20 Oct 2020 07:00 AM
RNS
Tagrisso adjuvant lung cancer US Priority Review
19 Oct 2020 07:00 AM
RNS
Forxiga HF receives positive CHMP opinion
19 Oct 2020 07:00 AM
RNS
Trixeo Aerosphere receives positive CHMP opinion
12 Oct 2020 07:00 AM
RNS
COVID-19 antibodies advance and get US funding
02 Oct 2020 07:00 AM
RNS
Farxiga granted US BTD in chronic kidney disease
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100